IL2 and mature T-cell and NK-cell non-Hodgkin lymphoma: Denileukin diftitox, a fusion protein linking diphtheria toxin to IL-2, elicited an ORR of 65% when used in combination with CHOP chemotherapy in a cohort of newly diagnosed PTCL alongside well-tolerated side effect profiles (109); applied to a cohort of R/R PTCL, it was able to elicit an ORR of 61.5% in CD25+ patients and 45.5% in CD25- patients (110).